Shares of Regeneron Pharmaceuticals Inc. slipped 3.63% to $527.78 Friday, on what proved to be an all-around poor trading ...

The primary endpoint of comprehensive disease control was defined as a combination of clinical remission (CDAI under 150; ...

Regeneron Pharmaceuticals Inc. closed 54.78% below its 52-week high of $1,211.20, which the company reached on August 27th.

A prior phase II trial had shown that BCG revaccination in teens led to 45.4% efficacy in reversion from positive to negative ...

Improvements in Scalp Itch-Numeric Rating Scale (SI-NRS) were greater in the roflumilast group than for the vehicle group, ...

An ex-assistant U.S. attorney in Los Angeles has filed a claim calling his dismissal “unlawful” and alleging it was motivated ...

The findings are based on dietary recall, which points toward further research rather than specific recommendations.

We recently compiled a list of the 10 Jim Cramer Stocks with Huge Upside Potential. In this article, we are going to take a ...

This was the stock's second consecutive day of losses.

The new plans are in addition to $21B that the drug manufacturer has already committed to U.S. research, development and ...

We recently published a list of Billionaire Mario Gabelli’s 10 Large-Cap Stock Picks with Huge Upside Potential. In this ...

With President Donald Trump expected to deliver a drug pricing order on Monday that Big Pharma and patient groups alike have ...